Fusion Antibodies & Analytics Engines to Incorporate Artificial Intelligence into Its World Class Antibody Humanization Service
26 November 2018 - 8:00PM
Business Wire
Fusion Antibodies plc, experts in antibody engineering and
Analytics Engines, an advanced data analytics company, have
announced a strategic collaboration to incorporate machine learning
(ML) and artificial intelligence (AI) into Fusion Antibodies’ CDRx™
humanization platform. This collaboration will boost Fusion
Antibodies’ continual efforts to improve its algorithms to
understand the structure/function relationship of its target
antibodies. The CDRx™ platform makes it possible to perform
multiple virtual experiments with panels of selected
antibodies to discover properties that meet desired functionality
and developability requirements with the long-term goal of reducing
development costs and accelerating timelines so that novel antibody
drugs can reach patients faster.
“We are delighted to have the opportunity to collaborate with
the team at Analytics Engines to incorporate artificial
intelligence into our CDRx™ platform. At Fusion Antibodies we want
to keep differentiating our product to make sure it’s the best
humanization platform in the world, and that’s our goal, keeping
ourselves in front. Collaborating with Analytics Engines will allow
us to drive up our quality and add more certainty and
manufacturability to the products,” said Paul Kerr, CEO of Fusion
Antibodies.
“Analytics Engines are excited to be part of this collaboration,
assisting Fusion Antibodies in taking the CDRx platform to the next
level. Using our expertise in Machine Learning and AI, Fusion
Antibodies will be able to create ML models to continually improve
their antibody humanization process” said Aislinn Rice, CEO of
Analytics Engines.
About Fusion Antibodies plc
Fusion Antibodies is a world leading Contract Research
Organisation (CRO), established in 2001. Working with an
international client base, Fusion Antibodies provides services
covering all aspects of antibody development including stable cell
line development.
Fusion Antibodies is a publicly held company, trading on the
London Stock Exchange (LSE FAB.L) with headquarters in Belfast,
Northern Ireland. Our world class services, unrivalled expertise
and commitment to clients make Fusion Antibodies your first choice
for the development of antibodies for both therapeutic drug and
diagnostic applications.
We understand what is important to you. At Fusion Antibodies we
designed a pipeline of services to accelerate your program into the
clinic. We offer a complete range of antibody services in
Discovery, Engineering and Supply. With multiple client antibodies
in phase 1 and 2 trials we begin each project with the end in mind,
to deliver the best possible antibodies.
To find out how Fusion Antibodies can help accelerate your
program into the clinic visit www.fusionantibodies.com.
About Analytics Engines
Analytics Engines is a global leader in the delivery and
implementation of advanced Data Analytics Solutions. Headquartered
in Belfast, Analytics Engines employs 20 people with expertise in
data infrastructure, data engineering, artificial intelligence and
machine learning, data analytics and visualizations.
Analytics Engines technology and expertise enables organisations
to convert data into valuable business insights. We have developed
a range of high-value solutions within the healthcare, government
and private sectors. Built upon the Analytics Engines XDP™ data
platform, the company has also developed a range of products for
smart cities, healthcare, and governmental bodies.
To find out how Analytics Engines can help you gain value from
you data visit us at – www.analyticsengines.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181126005083/en/
Fusion Antibodies plcDr. Paul Kerr, CEOEmail:
paul.kerr@fusionantibodies.comWebsite:
www.fusionantibodies.comAnalytics EnginesDr. Aislinn Rice,
CEOEmail: a.rice@analyticsengines.comWebsite:
www.analyticsengines.com
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2024 to May 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From May 2023 to May 2024